Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Summit Therapeu ADR (SMMT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,427
  • Shares Outstanding, K 13,844
  • Annual Sales, $ 57,060 K
  • Annual Income, $ 9,990 K
  • 60-Month Beta 1.42
  • Price/Sales 0.40
  • Price/Cash Flow 1.44
  • Price/Book 0.40

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/19
See More
  • Average Estimate -0.31
  • Number of Estimates 3
  • High Estimate -0.26
  • Low Estimate -0.40
  • Prior Year -0.55
  • Growth Rate Est. (year over year) +43.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.55 +2.58%
on 05/15/19
1.99 -20.10%
on 04/25/19
-0.27 (-14.52%)
since 04/24/19
3-Month
1.41 +12.77%
on 02/25/19
2.46 -35.37%
on 02/27/19
+0.25 (+18.66%)
since 02/22/19
52-Week
1.10 +44.55%
on 01/02/19
13.76 -88.44%
on 05/30/18
-11.63 (-87.97%)
since 05/24/18

Most Recent Stories

More News
Detailed Research: Economic Perspectives on Patterson-UTI Energy, Take-Two Interactive Software, DXC Technology, Ingevity, Summit Therapeutics, and Kinsale Capital Group -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Patterson-UTI Energy, Inc....

NGVT : 87.43 (+1.36%)
SMMT : 1.59 (-1.85%)
PTEN : 11.04 (-3.24%)
DXC : 53.08 (+2.12%)
TTWO : 105.02 (+0.61%)
KNSL : 85.40 (+1.59%)
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that twelve of its member companies...

MLNT : 2.64 (-6.05%)
ETTX : 6.34 (+1.44%)
ITRM : 6.26 (-0.63%)
CFRX : 0.40 (-2.49%)
MTFB : 1.83 (+5.84%)
SMMT : 1.59 (-1.85%)
SCYX : 1.28 (+4.07%)
CDTX : 1.92 (+1.05%)
NBRV : 2.38 (+6.73%)
PRTK : 4.18 (-1.18%)
New Research Coverage Highlights Global Payments, Tableau Software, Summit Therapeutics, Utah Medical Products, Apollo Commercial Real Estate Finance, and Urstadt Biddle Properties -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Global Payments Inc. (NYSE:GPN),...

UTMD : 81.22 (+4.45%)
GPN : 153.44 (+3.70%)
DATA : 112.94 (+0.27%)
UBA : 22.55 (+0.04%)
SMMT : 1.59 (-1.85%)
ARI : 18.76 (+0.64%)
Antimicrobials Working Group Announces Updates to Leadership Team

The Antimicrobials Working Group (AWG) announced today the appointment of a new Chairman, Evan Loh, M.D., President, Chief Operating Officer and Chief Medical Officer of Paratek Pharmaceuticals, Inc. Dr....

MLNT : 2.64 (-6.05%)
ITRM : 6.26 (-0.63%)
CFRX : 0.40 (-2.49%)
MTFB : 1.83 (+5.84%)
SMMT : 1.59 (-1.85%)
SCYX : 1.28 (+4.07%)
CDTX : 1.92 (+1.05%)
NBRV : 2.38 (+6.73%)
PRTK : 4.18 (-1.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade SMMT with:

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

2nd Resistance Point 1.72
1st Resistance Point 1.66
Last Price 1.59
1st Support Level 1.56
2nd Support Level 1.52

See More

52-Week High 13.76
Fibonacci 61.8% 8.92
Fibonacci 50% 7.43
Fibonacci 38.2% 5.94
Last Price 1.59
52-Week Low 1.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar